Soffinova Partners

About The Fund

Sofinnova Partners is a leading investment firm that specializes in the life sciences sector, with a keen focus on supporting innovative companies throughout their growth journey. Since its founding in 1972, Sofinnova Partners has been committing to transformative companies that aim to address the world's most pressing challenges in healthcare and sustainability. With a hands-on approach and a commitment to building long-term relationships built on trust and transparency, they nurture their portfolio companies throughout their development phases. Sofinnova Partners has a broad investment range, typically between €100,000 and €5,000,000, with a sweet spot around €1,500,000, primarily directing funds toward Seed, Series A, and Series B ventures. With assets under management totaling approximately €548 million, Sofinnova Partners operates a variety of specialized funds, each with a unique investment thesis. Their strategies cover the entire value chain of life sciences investments, from seed to later-stage. The Sofinnova Capital Strategy focuses on early-stage biopharma and medtech start-ups pioneering groundbreaking therapeutic technologies. The Sofinnova MD Start Strategy, an in-house medtech accelerator, leverages hands-on entrepreneurial expertise to lead company building in the medtech sphere globally. Their Crossover Strategy targets later-stage biotech and medtech companies, propelling them to reach their full potential.Distinctively, they also have the Sofinnova Industrial Biotech Strategy that invests in early-stage companies poised to impact sustainability positively across various sectors like chemicals, agriculture, food, and materials. The Sofinnova Telethon and Biovelocita Strategies are oriented towards bringing formidable scientific research from Italy and Europe to the forefront of the global stage. Lastly, the Sofinnova Digital Medicine Strategy invests in early-stage startups at the intersection of biology, data, and computation to harness the power of digital transformation in medicine.Over the past five decades, Sofinnova Partners has built a legacy of over 500 companies in its portfolio, establishing itself as a company creator and a steadfast partner in the evolution of the life sciences industry. Their investment philosophy is deeply rooted in the conviction that investing in patient-centric solutions not only saves lives but also yields a significant financial return.